Epidemiological Pattern of Rubella in Africa: A Review of Selected Sub-Saharan African Countries https://doi.org/10.60787/NMJ-63-5-131
Main Article Content
Keywords
Rubella, Epidemiology, sub-saharan Africa
Abstract
Rubella (German measles) is vaccine-preventable and a viral disease of public health importance. It presents with mild febrile rash illness, attendant congenital sequelae and foetal death. This paper seeks to do a review of the epidemiology of rubella in selected sub-Saharan African countries. This is a review of literature involving data triangulation of rubella surveillance data. World Health Organization (WHO)rubella surveillance data (2015-2018) was available online to present the seasonal/time-variation. Data were extracted from the site into Microsoft Excel over three months (October-December, 2018). Univariate data analysis was done using SPSS-23, and data were presented with appropriate tables and charts to show the trend.
Epidemiologic findings showed that the periodicity of rubella varies across countries in Africa, with seasonal variation across the four sub-regions. In the West Africa sub-region, sharp increases occurred in reported cases in January, with peaks in March-April. In Nigeria, a West African country, available data showed that seasonal peak occurs in the first four months (Jan-April) of the year, with most of the burden among those below fifteen years of age affecting both sexes and incidence cuts across both rural and urban areas. However, in the Central sub-region, spikes generally occur between February and March with troughs from September to November. In the East sub-region, dual peaks occur in March-April and in September-October; in the South sub-region, unique annual seasonality with few cases reported in January-June each year. The peak incidence of rubella has been observed to be a function of the seasonal peaks/variation in Africa. Therefore, the knowledge of this seasonal variation can be leveraged upon by Governments to control the disease through scaling up of awareness creation and surveillance during the identified peaks and beyond.
References
2.Gadallah M, El Sayed N, Kandeel A, Moussa I, Mohsen A, Dewadar S. Seroprevalence of rubella antibodies among adult Egyptian females aged 20-30 years. Is there a need for rubella vaccination? Central EuropeanJournal of Public Health2014;22:282-286.
3.Suleiman ST, Bakare R, Akanbi II AA, Fowotade A, Biliaminu SA, Durowade KA. Recent rubella infection among childbearing women in a tertiary hospital in Nigeria: A sero-epidemiological indication for vaccination need. African Journal of Clinical andExperimental Microbiology2016;17: 213-218.
4.Chimhuya S, Manangazira P, Mukaratirwa A, Nziramazanga P, Berejena C, Shonhai A et al. Trends of rubella incidence during a 5-year period of case-based surveillance in Zimbabwe. BMC Public Health2015; 15: 294-301.
5.Lee JY, Bowden DS. Rubella virus replication and links to teratogenicity. ClinicalMicrobiology Reviews2000;13: 571-587.
6.Kaushal M, Baxi A. Rubella immune status of pregnant and non-pregnant women in Indian population. The Internet Journal ofGynecology and Obstetrics2006;6:1-5
7.Tamirat B, Hussen S, Shimelis T. Rubella virus infection and associated factors among pregnant women attending the antenatal care clinics of public hospitals in Hawassa City, Southern Ethiopia: a cross sectional study. BMJ Open2017; 7:e016824-e016831.
8.Ouyahia A, Segueni A, Laouamri S, Touabti A, Lacheheb A. Seroprevalence of rubella among women of childbearing age in Algeria. Is there a need for a rubella vaccination? InternationalJournal of Public Health and Epidemiology2013; 2: 55-59
9.Agbede OO, Adeyemi OO, Olatinwo AWO, Salisu TJ, Kolawaole OM. Sero-prevalence of antenatal rubella in UITH. The Open PublicHealth Journal2011; 4:10-16.
10.Kolawaole OM, Adekeye O. High prevalence of rubella immunoglobulin G seropositivity among pregnant women in Ilorin, Kwara state, Nigeria. Nigerian Journal of Pure and AppliedSciences2017;30: 3030-3036.
11.Suleiman ST, Bakare R, Akanbi II AA, Fowotade A, Biliaminu SA, Durowade KA. Rubella antibody avidity among rubella seropositive women attending a tertiary care facility in Nigeria. International Journal ofWomen's Health Research2015;3:136-141.
12.Kolawole OM, Anjonrin EO, Adekanle DA, Kolawole CF, Durowade KA. Seroprevalence of Rubella IgG antibody in pregnant women in Osogbo, Nigeria. International Journal ofPreventive of Medicine2014;5:287-292.
13.Goodson JL, Masresha B, Dosseh A, Byabamashima C, Nshimirimana G,Cochi S, Reef S. Rubella epidemiology in Africa in the prevaccine era, 2002–2009. Journal of Infectious Diseases2011;204(suppl 1): S215-S225.
14.Mwambe B, Mirambo MM, Mshana SE, Massinde AN, Kidenya BR, Michael, D et al. Sero-positivity rate of rubella and associated factors among pregnant women attending antenatal care in Mwanza, Tanzania. BMCPregnancy Childbirth2014;14: 95-99.
15.Kombich JJ, Muchai PC, Tukei P, Borus PK. Rubella seroprevalence among primary and pre-primary school pupils at Moi's Bridge location, Uasin Gishu District, Kenya. BMCPublic Health2009;9:269-273.
16.Jonas A, Cardemil CV, Beukes A, Anderson R, Rota PA, BankampB et al. Rubella immunity among pregnant women aged 15-44 years, Namibia, 2010. International Journal ofInfectious Diseases2016;49: 196-201.
17.Wondimeneh Y, Tiruneh M, Ferede G, AberaB, Workineh M, Birhanie M et al. Rubella virus infections and immune status among pregnant women before the introduction of rubella vaccine in Amhara Regional State, Ethiopia. InternationalJournal of Infectious Diseases2018;76: 14-22.
18.Luce R, Masresha BG, Katsande R, Fall A, Shibeshi ME. The impact of recent rubella vaccine introduction in 5countries in the African region. Journal of ImmunologicalSciences2018; S016: 108-112.
19.Farra A, Pagonendji M, Manikariza A, Rawago D, Ouambita-Mabo R, Guifara G et al. Epidemiology of primary rubella infection in the Central African Republic: data from measles surveillance, 2007-2014. BMCInfectious Diseases2016;16: 505-510.
20.Mitiku K, Bedada T, Masresha B, Kegne W, Nafo-Traore F, Tesfaye N et al. The epidemiology of rubella disease inEthiopia: data from the measlescase-based surveillance system. Journal of Infectious Diseases2011; 204(Supp 1): 5239-5242.
21.Junaid SA, Akpan KJ, Olabode AO. Sero-survey of rubella IgM antibodies among children in Jos, Nigeria. Virology Journal2011; 8: 244-248
22.Getahun M, Beyene B, Gallagher K, Ademe A, Teshome B, Tefera M et al.Epidemiology of rubella virus cases in the pre-vaccination era of Ethiopia, 2009-2015. BMC Public Health2016; 16: 1168-1174.
23.Schoub BD, Harris BN, McAnerney J, Blumberg L. Rubella in South Africa: An impending Greek tragedy? Southern AfricanMedical Journal2009;99: 515-519.
24.Manirakiza K, Kipela JM, Sosler S, Daba RM, Gouandjika-Vasilache, I. Sero-prevalence of measles and natural rubella antibodies among children in Bangui, Central African Republic.BMC Public Health2011;11:327-333.
25.Winter AK, Martinez ME, Cutts FT, Moss WJ, Ferrari MJ, Mckee A et al. Benefits andChallenges in using seroprevalence data to inform models for Measles and Rubella Elimination. Journal of Infectious Diseases2018; 218: 355-364.
26.Omoleke SA, Udenenwu HC. Incidence of rubella in a state in North-western Nigeria: a call for action. Pan African Medical Journal2016; 25: 49-54.
27.Fatiregun AA, Fagbamigbe AF, Adebowale AS. Epidemiology of rubella surveillance in south-west Nigeria: trends and projection from measles case-based surveillance data. Southern African Journal of Infectious Diseases2014;29:60-64.
28.Yahaya H, Ibrahim A, Ahmad IM, Yunusa, I. Rubella prevalence in Nigeria (1977-2015): An Update review on the impact. Annals ofExperimental Biology2017;5:15-21.
29.Durowade KA, Musa OI, Jimoh MA, Salaudeen AG, Bolarinwa OA, Bakare OQ et al. Burden, epidemiological pattern, and surveillance gap of rubella in Nigeria: A call for routine vaccination policy. Indian Journalof Health and Biomedical Research KLEU2021;14:31-37
30. World Health Organization. Provisional monthly measles and rubella data. Retrieved November 25, 2018 from https://www.who.int › teams › surveillance › monitoring.
